CompletedNCT03730857
Early Signs of Treatment Response to Antipsychotics in Schizophrenia
About this title
Read the official source — NCT03730857Medication studyAges 18–65
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: January 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 111
- Sponsor
- Calo Psychiatric Center
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03730857
- Official title
Show the full official title
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Calo Psychiatric Center.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, risperidone and Paliperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
